

iZafe Group's CEO, deputy CEO and board intend to subscribe for shares in the current redemption of options for series TO 8 B

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B), a leading life science company in the digitalisation of medication management, has announced that its CEO, deputy CEO and board members intend to utilise their options from series TO 8 B to subscribe for shares. During November 2019, iZafe carried out a rights issue of units including TO 8 B shares and options. The subscription period for TO 8 B is in progress and ends on 18 December 2020. The subscription price has been set at SEK 3.30 per B share. The intention to subscribe equates to an issue of 113,471 shares in total.

"During this year, iZafe Group has assumed a position as a leading player in the market for digital medication management. As a pure life science company with our medication dispensing robot Dosell we have made huge progress, and we are continuing to develop the business at a rapid pace. The capital contribution from the subscription to shares in TO 8 B will create further conditions for the commercialisation and widespread introduction of Dosell in the Nordic countries and in Italy," commented Anders Segerström, CEO of iZafe Group.

The declarations of intent have not been secured via advance transaction, bank guarantee or similar.

Advisors

Stockholm Corporate Finance AB is the financial advisor, KANTER Advokatbyrå KB is the legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing body connected to the option redemption.

About Stockholm Corporate Finance

Stockholm Corporate Finance is an independent, privately owned financial consultancy offering qualified consultancy services relating to capital procurement, changes of ownership, acquisitions, mergers and disposals (M&A) to listed and private companies and their owners. Stockholm Corporate Finance is an exclusive Swedish partner in the global network M&A Worldwide, which is made up of 46 M&A consultants and investment bankers in 38 countries. Stockholm Corporate Finance is a securities company regulated by the Swedish Financial Supervisory Authority and is a member of the sector organisation SwedSec Licensiering AB.

For more information see: www.stockholmcorp.se.

Contacts

Thomas Ahlerup, Chairman of the board and Investor Contact

E-mail: thomas.ahlerup@izafegroup.com

Phone number: +46-7868-966 300

iZafe Group AB (publ)

Grev Turegatan 11A

114 46 Stockholm

E-mail: ir@izafegroup.com

www.izafegroup.com/investorrelations

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafegroup.com/investorrelations.

Attachments

[iZafe Group's CEO, deputy CEO and board intend to subscribe for shares in the current redemption of options for series TO 8 B](#)